<DOC>
	<DOC>NCT01237665</DOC>
	<brief_summary>This is a prospective open label single-arm, single-institution phase II clinical trial to test the efficacy of neoadjuvant treatment with IXO (Irinotecan, Capecitabine [Xeloda], Oxaliplatin) followed by chemoradiotherapy and resection in patients with resectable non-metastatic primary rectal cancer of stage cT3-T4 N0-N2.</brief_summary>
	<brief_title>IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>General Pathologically confirmed rectal adenocarcinoma T3 or T4 or N1 (node ≥1 cm on short axis) adenocarcinoma of the rectum. ECOG performance status equal or less than 1 Male and female patients, aged ≥ 18 years and ≤ 80 years Written informed consent Adequate haematological, liver, renal function Resectability Patients categorized as having resectable locally advanced cancer Favorable general condition Resectability Diagnosis of metastatic disease Clear indication of involvement of pelvic wall(s), on imaging. Peritoneal carcinomatosis, portal vein occlusion, ascites, nonregional lymph nodes Histology other than adenocarcinoma Obstructed rectal carcinoma without defunctionalizing colostomy Prior treatment Previously undergone treatment for this disease Prior chemotherapy for colorectal cancer Prior chemotherapy for other malignancies in past 12 months Prior radiotherapy other than skin cancer Concomitant use of St John's Wort Treatment with any other investigational agent Current use of fulldose of warfarin for therapeutic Other conditions Confirmed or suspected brain metastases History or evidence of CNS disease Past or current history of other malignancies Clinically significant cardiovascular disease Evidence of bleeding diathesis or coagulopathy Known hypersensitivity to any of the study drugs Serious, nonhealing wound, ulcer or bone fracture Major surgical procedure or significant traumatic injury within 28 days prior to treatment Disease or condition that contraindicates the use of an investigational drug Life expectancy less than 5 years Inability or unwillingness to comply with the protocol Neuropathy ≥ Gr.2 History of ulcerative colitis or Crohn's disease Pelvic abscess or perforated pelvic carcinoma Pregnancy / Contraception Pregnancy or lactation Positive serum pregnancy test within 7 days of starting study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>locally resectable advanced adenocarcinoma of the rectum</keyword>
</DOC>